Results 181 to 190 of about 968,734 (398)

Relative Antigenic Potency in Man of Polyvalent Influenza Virus Vaccines Containing Isolated Hemaggi Utinins or Intact Viruses [PDF]

, 1966
Albert V. Hennessy, Fred M. Davenport
openalex   +1 more source

Molecular dynamics of the host response to Streptococcus pneumoniae pneumonia in baboons

Animal Models and Experimental Medicine, EarlyView.
Using an established, clinically relevant nonhuman primate model of S. pneumoniae pneumonia, this study aims to identify novel potential molecular diagnostic and therapeutic targets using peripheral blood bulk transcriptomic, unbiased proteomic, and cytokine measurements. The constructed models were highly accurate in classifying bacterial pneumonia in
Bryan D. Kraft, Ashlee M. Valente, Ephraim L. Tsalik, Micah T. McClain, Marshall Nichols, Thomas W. Burke, Ricardo Henao, Erik J. Soderblom, J. Will Thompson, M. Arthur Moseley, Lori L. Hudson, Timothy Veldman, Olga M. Better, Mert Aydin, Anna Mazur, Karen E. Welty‐Wolf, Claude A. Piantadosi, Geoffrey S. Ginsburg, Christopher W. Woods   +18 more
wiley   +1 more source

Antibody response and reactions to aqueous influenza vaccine, simple emulsion vaccine and multiple emulsion vaccine. A report to the Medical Research Council Committee on influenza and other respiratory virus vaccines [PDF]

, 1969
Patricia J. Taylor, Christine L. Miller, T.M. Pollock, F. T. Perkins, M. A. Westwood   +4 more
openalex   +1 more source

Influenza Vaccine

, 2021
The influenza virus circulates continuously, causing regional epidemics and outbreaks, leading to thousands of deaths. For instance, according to the Centers for Disease Control and Prevention (CDC) data statistics, more than 13 million flu cases were recorded so far in the 2019-20 timeframe.
openaire   +1 more source

Silica Nanoparticles as Multifunctional Platforms for Vaccine Delivery and Immune Modulation in Infectious Diseases

Advanced NanoBiomed Research, EarlyView.
Overview of the use of silica nanoparticles in vaccines against pathogens. Different kinds of vaccines against infectious diseases are currently using solid or mesoporous silica nanoparticles in their formulation. Silica microparticles and nanoparticles (SiNPs) have been studied as vehicles for vaccines.
Noe Juvenal Mendoza‐Ramírez, Julio García‐Cordero, Gabriela Navarro‐Tovar, Leticia Cedillo‐Barrón   +3 more
wiley   +1 more source

Advances in protein subunit vaccines against H1N1/09 influenza

Frontiers in Immunology
The A/H1N1pdm09 influenza virus, which caused the 2009 pandemic, has since become a recurring strain in seasonal influenza outbreaks. Given the ongoing threat of influenza, protein subunit vaccines have garnered significant attention for their safety and
Yu Zhang, Yu Zhang, Jingyao Gao, Wenqi Xu, Xingyu Huo, Jingyan Wang, Yirui Xu, Wenting Ding, Zeliang Guo, Rongzeng Liu   +9 more
doaj   +1 more source

Allergy to influenza vaccine. [PDF]

, 1968

openalex   +1 more source

Polysaccharide‐Coated ETCA Nanoparticles Containing the Methoxyl Substituted Indole‐Thiazole Derivative and Their Antiproliferative Activity in Breast Cancer Cells

Journal of Applied Polymer Science, EarlyView.
ABSTRACT Indole and thiazole derivatives have garnered significant attention due to their potent antitumor activities. Encapsulation of such derivatives into polymeric nanoparticles offers several advantages, including improved molecular stability and targeted delivery to tumor sites, thereby enhancing their antineoplastic potential.
José Cleberson Santos Soares, Iago Dillion Lima Cavalcanti, Iranildo José da Cruz‐Filho, Mariane Cajubá de Britto Lira Nogueira, Maria do Carmo Alves de Lima   +4 more
wiley   +1 more source

Influenza infections during pregnancy: association with congenital malformations and with subsequent neoplasms in children, and potential hazards of live virus vaccines. [PDF]

, 1974
J. S. Mackenzie, M Houghton
openalex   +2 more sources

Comparative efficacy and safety of anakinra and canakinumab in patients with VEXAS syndrome – an international multicenter study

Arthritis &Rheumatology, Accepted Article.
Objectives The aim of this study was to compare differences in clinical response, drug survival, and adverse event rates between anakinra and canakinumab in VEXAS syndrome. Methods This multicenter international study includes VEXAS patients from France, Israel, and Italy treated with IL1 inhibition (IL1i).
Tali Eviatar, Dafne Capelusnik, Corrado Campochiaro, Valentin Lacombe, Vincent Jachiet, Michael Zisapel, Iftach Sagy, Oshrat E. Tayer‐Shifman, David Ozeri, Shaye Kivity, Alessandro Tomelleri, Benjamin Terrier, Hagit Peleg, Thibault Comont, Karim Sacre, Pascal Woaye‐Hune, Laurent Arnaud, Estibaliz Lazaro, Vincent Grobost, Francois Lifermann, Maxime Samson, Samuel Ardois, Alice Garnier, Alexandre Maria, Alain Cantagrel, Aurore Meyer, Jean‐David Bouaziz, Mael Heiblig, Lorenzo Dagna, Elisa Diral, Olivier Kosmider, Ori Elkayam, Jérôme Hadjadj, Sophie Georgin‐Lavialle, Olivier Fain, Arsene Mekinian   +35 more
wiley   +1 more source